OncoMatch/Clinical Trials/NCT06533579
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Is NCT06533579 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies non-drug interventions for b-cell acute lymphoblastic leukemia.
This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19-positive hematologic malignancies.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Chronic Lymphocytic Leukemia
Acute Myeloid Leukemia
Biomarker criteria
Required: CD19 positive expression (positive)
CD19-positive expression
Demographics
Prior therapy
Must have received:
Relapsed or refractory CD-19 positive leukemia or lymphoma
Cannot have received: chemotherapy
Exception: given within the protocol-specified discontinuation timelines
Chemotherapy given within the protocol-specified discontinuation timelines
Lab requirements
Blood counts
protocol-specified ranges
Kidney function
protocol-specified ranges
Liver function
AST or ALT ≤ 2x upper limit of normal
Cardiac function
protocol-specified ranges
Protocol-specified ranges for renal, liver, cardiac and pulmonary function; Protocol-specified ranges for hematology parameters; Hepatoxicity (AST or ALT > 2x upper limit of normal) [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope · Duarte, California
- Valkyrie Clinical Trials · Los Angeles, California
- Colorado Blood Cancer Institute · Denver, Colorado
- New York Medical College · Valhalla, New York
- University of North Carolina at Chapel Hill/ University of North Carolina Medical Center · Chapel Hill, North Carolina
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06533579 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior chemotherapy disqualifies patients from enrollment.
Does this trial require CD19?
Yes, CD19 positive expression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 90 years or younger and at least 13 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify